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Introduction
Pyogenic sterile Arthritis Pyoderma gangrenosum and
Acne (PAPA) syndrome is a rare autosomal dominant
inherited autoinflammatory disease caused by mutations
of Proline-serine-threonine phosphatase-interacting pro-
tein 1 (PSTPIP1). In childhood, the syndrome is featured
by recurrent sterile, erosive arthritis, potentially leading
to joint destruction. By puberty, cutaneous symptoms
become predominant, with recurrent onset of pathergy,
abscesses, severe cystic acne, and pyoderma gangreno-
sum. Typically, both articular and cutaneous outcomes
occur following a minor trauma. PSTPIP1 may interact
with ASC and caspase-1 but a clear involvement of
interleukin (IL)-1b and the role of NLRP3 is still contro-
versial. While anti-IL1 treatment seems to be effective
on joint manifestations, IL inhibition does not display
the same effectiveness in the management of skin
lesions.
Objectives
To investigate in our PAPA cohort whether IL1b secre-
tion 1) is enhanced, 2) correlates with different PSTPIP1
mutations, clinical manifestations and/or disease activity,
and 3) is mediated by NLRP3.
Methods
Eleven genetically confirmed patients (N = 2 children and
N = 9 adults) carrying different PSTPIP1 mutations
(E250K N = 1, E256G N = 1, E250Q N = 9) were ana-
lyzed and compared to 31 healthy donors (HD). Four
patients had an active disease at the time of sampling
while 7 were symptom-free. Nine out of 11 were off-ther-
apy. Peripheral blood primary human monocytes were
freshly isolated and studied at baseline and after 3-6-18
hours (h) of LPS-induced in vitro activation. Pattern of
IL-1b secretion was assessed by ELISA. The involvement
of NLRP3 was investigated by in vitro silencing.
Results
Monocytes isolated from PAPA patients tent to secrete
higher levels of IL-1b but this was not consistent in all the
patients (p = 0.144). Variability in IL-1b release occurred
even in the presence of the same PSTPIP1 variant and it
did not parallel disease activity when the whole cohort was
taken in consideration. However, IL-1b levels varied
according to the clinical picture (p = 0.0197), and it was
significantly higher (P < 0.05) in patients displaying articu-
lar manifestations (N = 3) compared to those affected by
cutaneous (N = 6) or combined (N = 2) lesions. In the for-
mer, IL-1b secretion was increased in the presence of
acute phase reactants elevation and active joint lesions,
and treatment with Anakinra resulted in acute phase reac-
tans normalization and symptom-free period. Silencing of
of NLRP3 activity consistently inhibited LPS-induced
IL-1b release in both PAPA and HD monocytes.
Conclusion
IL-1b secretion is higher in PAPA patients displaying
prevalent articular manifestations. In these patients,
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